The clinical efficacy and safety of micafungin–itraconazole combination therapy in patients with pulmonary aspergilloma

Stevens, 2000, Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America, Clin Infect Dis, 30, 696, 10.1086/313756 Tekaia, 2005, Aspergillus fumigatus: saprophyte or pathogen?, Curr Opin Microbiol, 8, 385, 10.1016/j.mib.2005.06.017 Upton, 2007, Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality, Clin Infect Dis, 44, 531, 10.1086/510592 Kohno, 2004, A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan, Scand J Infect Dis, 36, 372, 10.1080/00365540410020406 Tubura, 1997, Pulmonary Aspergilloma Study Group. Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma, Kekkaku, 72, 557 Brouwer, 2004, Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomized trial, Lancet, 363, 1764, 10.1016/S0140-6736(04)16301-0 Ikeda, 2007, Role of micafungin in the antifungal armamentarium, Curr Med Chem, 14, 1263, 10.2174/092986707780597970 Ouchi, 2007, Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin, J Infect Chemother, 13, 258, 10.1007/s10156-007-0524-9 Espinel-Ingroff, 2003, In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature, Rev Iberoam Micol, 20, 121 Okamoto, 2006, Successful treatment of invasive sinus aspergillosis with micafungin and itraconazole, Kansenshogaku Zasshi, 80, 115, 10.11150/kansenshogakuzasshi1970.80.115 Johnson, 2004, Combination antifungal therapy, Antimicrob Agents Chemother, 48, 693, 10.1128/AAC.48.3.693-715.2004 Semighini, 2001, New restriction fragment length polymorphism (RFLP) markers for Aspergillus fumigatus, FEMS Immunol Med Microbiol, 31, 15, 10.1111/j.1574-695X.2001.tb01580.x Hashimoto, 1998, Comparison of PCR, (1–3)-beta-d-glucan and galactomannan assays in sera of rats with experimental invasive aspergillosis, J Clin Lab Anal, 12, 257, 10.1002/(SICI)1098-2825(1998)12:5<257::AID-JCLA1>3.0.CO;2-3 Kohno, 2010, Clinical efficacy and safety of micafungin, a novel echinocandin antifungal drug, in pulmonary aspergillosis in a postmarketing setting, Jpn J Chemother, 58, 128 Higashiyama, 2004, Micafungin: a therapeutic review, Expert Rev Anti Infect Ther, 2, 345, 10.1586/14787210.2.3.345 Clemons, 2006, Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions, Curr Opin Infect Dis, 19, 360, 10.1097/01.qco.0000235163.70678.59 Kontoyiannis, 2009, Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis, Transpl Infect Dis, 11, 89, 10.1111/j.1399-3062.2008.00349.x Denning, 2006, Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis, J Infect, 53, 337, 10.1016/j.jinf.2006.03.003 Marr, 2004, Combination antifungal therapy for invasive aspergillosis, Clin Infect Dis, 39, 797, 10.1086/423380 Kontoyiannis, 2003, Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies, Cancer, 98, 292, 10.1002/cncr.11479 Singh, 2006, Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study, Transplantation, 81, 320, 10.1097/01.tp.0000202421.94822.f7 Johnson, 2007, Combination antifungal therapy: what can and should we expect?, Bone Marrow Transplant, 40, 297, 10.1038/sj.bmt.1705687 Segal, 2008, Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria, Clin Infect Dis, 47, 674, 10.1086/590566